Huahai will invest more than 100 million yuan to build a pilot biological medicine laboratory in Shanghai

Source: Chen Baohua, deputy of the National People's Congress and general manager of Huahai pharmaceutical, said in an exclusive interview with the great wisdom news agency that he would invest more than 100 million yuan to build a biological medicine pilot laboratory in Shanghai this year Huahai pharmaceutical industry is transforming from APIs to preparations, and biosimilars are an important strategic layout of the company In May last year, the company signed an agreement with oncobiology to jointly operate and develop four monoclonal antibody generic drugs, including adamumumab for rheumatoid arthritis, rituximab for non Hodgkin lymphoma, bevacizumab for lung cancer and rectal cancer, and trastuzumab for breast cancer and rectal cancer According to the agreement, Huahai will enjoy 51% rights of the above products in the markets of developed countries in Europe and America and exclusive rights in the domestic market It is worth mentioning that adamumumab has been approved to carry out phase I clinical trials in the United States and the European Union, and bevacizumab has been approved to carry out phase I clinical trials in the European Union Chen Baohua said that after the completion of the pilot laboratory, the two drugs will be transferred to China for pharmacological and toxicological research as soon as possible, striving to keep pace with the progress of the United States and the European Union